Literature DB >> 32484898

Cost Analysis of Teleophthalmology Screening for Diabetic Retinopathy Using Teleophthalmology Billing Codes.

Michael P Ellis, Colin Bacorn, Kieu-Yen Luu, Sophie C Lee, Steven Tran, Christopher Lillis, Michele C Lim, Glenn Yiu.   

Abstract

BACKGROUND AND
OBJECTIVE: To evaluate the financial sustainability of teleophthalmology screening for diabetic retinopathy (DR) using telehealth billing codes. PATIENTS AND METHODS: The authors performed an Institutional Review Board-approved retrospective review of medical records, billing data, and quality metrics at the University of California Davis Health System from patients screened for DR through an internal medicine-based telemedicine program using CPT codes 92227 or 92228.
RESULTS: A total of 290 patients received teleophthalmology screening over a 12-month period, resulting in an increase in the DR screening rate from 49% to 63% (P < .0001). The average payment per patient was $19.86, with an estimated cost of $41.02 per patient. The projected per-patient incentive bonus was $43.06 with a downstream referral revenue of $39.38 per patient. One hundred seventy-eight clinic visits were eliminated, providing an estimated cost savings of $42.53 per patient.
CONCLUSION: Sustainable teleophthalmology screening may be achieved by billing telehealth codes but only with health care incentive bonuses, patient referrals, and by accounting for the projected cost-savings of eliminating office visits. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:S26-S34.]. Copyright 2020, SLACK Incorporated.

Entities:  

Mesh:

Year:  2020        PMID: 32484898     DOI: 10.3928/23258160-20200108-04

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN: 2325-8160            Impact factor:   1.300


  1 in total

1.  Trends in Remote Retinal Imaging Utilization and Payments in the United States.

Authors:  Sophie C Lee; Monica K Lieng; Susan Alber; Neesurg Mehta; Parisa Emami-Naeini; Glenn Yiu
Journal:  Ophthalmology       Date:  2021-10-12       Impact factor: 12.079

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.